Evaluating the impact of post-operative radiotherapy on high-grade skin cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness of post-operative radiotherapy (PORT) in patients with high-grade cutaneous squamous cell carcinoma (CSCC). It compares two cohorts: one that receives PORT and another that opts out despite its necessity. The study will evaluate the impact of PORT on recurrence rates and overall survival over a minimum follow-up period of 24 months. The findings could provide valuable insights into the role of PORT in managing this aggressive skin cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* diagnosis of high-grade cutaneous squamous cell carcinoma
* patients eligible for post-operative radiotherapy
* minimum follow-up of 24 months

Exclusion Criteria:

* lack of clinical of histological data
* impossibility of a proper follow-up
* occurrence of intermediate events (i.e., pregnancy)

Where it's running

• Fondazione IRCCS Policlinico San Matteo, SC Dermatologia
  Pavia, Pavia, Italy Recruiting

Study contacts

• Study coordinator: Chiara Giorgini, MD
• Email: c.giorgini@smatteo.pv.it
• Phone: +390382503498

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Seeing if the first lymph node helps detect skin cancer spread earlier

  They are testing whether checking the sentinel lymph node early can help see if high-risk skin squamous cell cancer has started to spread.

  Recruiting Germans Trias i Pujol Hospital · Badalona, Barcelona · NCT07746258

• Long-term real-world follow-up of adults with cutaneous squamous cell carcinoma needing systemic treatment in France

  This study tests how adults with cutaneous squamous cell carcinoma who require systemic therapy are managed in real life, using a national French database across multiple centers.

  Recruiting at 24 sites University Hospital, Lille · Amiens and 28 other locations · NCT07606508

• First-in-human test of KUP-101A in selected advanced skin cancers

  This early study tests KUP-101A to see if it's safe and tolerable and to gather initial clues about its activity in patients with advanced skin cancers.

  Recruiting at 3 sites Phase 1 Kupando GmbH · Munich, Bavaria and 2 other locations · NCT07600476

• Topical 5% Niacinamide for Skin Cancer Prevention in Organ Transplant Recipients

  This trial tests whether applying a 5% niacinamide cream daily, in addition to sunscreen, can reduce actinic keratoses and new skin cancers in adults who have had an organ transplant.

  Recruiting at 2 sites Early Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania and 1 other locations · NCT07286318

• Next‑generation immune profiling to find response and toxicity markers in skin cancer patients treated with cemiplimab

  This project will test whether advanced blood and tumor immune profiling can help predict who with advanced cutaneous squamous cell carcinoma will benefit from cemiplimab and who may develop side effects.

  Recruiting Instituto de Investigación Biomédica de Salamanca · Salamanca, Salamanca · NCT07064330

• MOHs Surgery and Short-Course Radiation for Head & Neck Skin Cancer

  This study tests whether a short course of radiation after Mohs surgery can prevent recurrence in high-risk cases, and whether some patients with moderate risk can be safely monitored without radiation.

  Recruiting Phase 2 University of Vermont Medical Center · Burlington, Vermont · NCT06998342

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.